Exelixis (EXEL) vs Halozyme Therapeutics (HALO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Halozyme Therapeutics (HALO) has outperformed Exelixis (EXEL) over the past year, gaining 69.6% versus a gain of 52.7%. Over five years, HALO leads with a +192.4% price change compared with +170.5% for EXEL. Exelixis is the larger company by market cap ($14.83 billion vs $12.53 billion), about 1.2 times the size, while Halozyme Therapeutics is growing revenue faster (+37.6% vs +7.0%).
On valuation, Halozyme Therapeutics trades at a lower forward P/E (10.4x vs 14.0x for Exelixis). Exelixis converts more of its revenue into profit, with a net margin of 33.7% versus 22.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | HALO |
|---|---|---|
| Share price | $59.86 | $110.42 |
| Market cap | $14.83B | $12.53B |
| 1-day change | +1.42% | +0.53% |
| YTD return | +34.66% | +64.07% |
| 1-year return | +52.74% | +69.59% |
| 5-year return | +170.49% | +192.43% |
| P/E ratio (TTM) | 18.59 | 32.10 |
| Forward P/E | 14.01 | 10.39 |
| EPS (TTM) | $3.22 | $3.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.32B | $1.40B |
| Revenue growth (YoY) | +6.98% | +37.55% |
| Net income (latest FY) | $782.57M | $316.89M |
| Gross margin | 96.39% | 83.62% |
| Operating margin | 37.59% | 33.58% |
| Net margin | 33.73% | 22.69% |
| 52-week high | $61.14 | $116.85 |
| 52-week low | $33.76 | $61.23 |
| Distance from 52-week high | -2.09% | -5.50% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -8.90% | -9.84% |
| Average volume | 2.34M | 2.18M |
| Shares outstanding | 247.78M | 113.50M |
| Employees | 1,077 | 423 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HALO has outperformed EXEL by 16.8 percentage points over the past year.
- Halozyme Therapeutics trades at a higher earnings multiple (32.1x vs 18.6x trailing P/E).
- Exelixis is more profitable, keeping 33.7 cents of every revenue dollar as net income versus 22.7 cents for Halozyme Therapeutics.
- Halozyme Therapeutics grew revenue faster in its latest fiscal year (+37.55% vs +6.98%).
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Halozyme Therapeutics
HALO stock →Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 423 employees
EXEL vs HALO FAQ
Which is bigger, Exelixis or Halozyme Therapeutics?
Exelixis (EXEL) is larger, with a market capitalization of $14.83B compared with $12.53B for Halozyme Therapeutics (HALO).
Which stock has performed better over the past year, EXEL or HALO?
HALO returned +69.59% over the past 12 months, compared with +52.74% for EXEL (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, EXEL or HALO?
EXEL has the lower trailing P/E at 18.6, versus 32.1 for HALO. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Exelixis and Halozyme Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.